Clinical Trial Update: ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating escalating doses of AGS-15ME as monotherapy in patients with metastatic urothelial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• AGS-15ME

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Metastatic Urothelial Cancer | Phase 1 | Status: COMPLETED